Unlocking The Potential of CFI as A Drug Target and Biomarker

Target Name: CFI

NCBI ID: G3426

Content of Review Report on CFI Target / Biomarker

CFI

Unlocking The Potential of CFI as A Drug Target and Biomarker

CFI, or Konglutinogen-activating factor, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the immune response and has been implicated in a number of diseases, including autoimmune disorders, inflammation, and fibrosis.

One of the unique features of CFI is its ability to activate the immune response, allowing it to be a valuable drug target for researchers. By targeting CFI, researchers can study its role in the immune response and develop new treatments for a variety of diseases.

CFI has also been shown to play a role in the regulation of inflammation, which is a major contributor to a number of chronic diseases, including heart disease, diabetes, and cancer. By inhibiting the activity of CFI, researchers may be able to develop new treatments for these diseases.

Another potential application of CFI as a drug target is its role in the regulation of fibrosis, a condition in which tissues become abnormally thick and can cause a variety of problems, including pain, swelling, and decreased function. CFI has been shown to play a role in the regulation of fibrosis by promoting the production of extracellular matrix (ECM) components, which are involved in tissue repair and regeneration.

In addition to its potential as a drug target, CFI is also of interest as a biomarker for a variety of diseases. Its expression has been shown to be affected by a number of factors, including inflammation, fibrosis, and certain medications. By studying the expression of CFI, researchers may be able to develop new diagnostic tests for these diseases and identify new potential treatments.

Overall, CFI is a protein that has the potential to be a valuable drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in the immune and inflammatory responses and to develop new treatments based on its properties.

Protein Name: Complement Factor I

Functions: Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins (PubMed:7360115, PubMed:17320177). Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces (PubMed:2141838, PubMed:9605165, PubMed:12055245). The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization (PubMed:28671664)

The "CFI Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFI comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets